Health State Utility Values in Juvenile Idiopathic Arthritis: What is the Evidence?
- 11 May 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in PharmacoEconomics
- Vol. 38 (9), 913-926
- https://doi.org/10.1007/s40273-020-00921-7
Abstract
Objectives The objectives of this systematic review were to identify health state utility values (HSUV) of children and adults with juvenile idiopathic arthritis in the literature and to assess whether HSUV were appropriately reported and could be used to inform parameter inputs for a model-based cost-utility analysis to inform decision making. Methods MEDLINE, EMBASE, PsycINFO, EconLit and CINAHL databases were searched in July 2019. Inclusion criteria were studies using preference-based instruments, targeting children or adults with juvenile idiopathic arthritis, and in the English language. The quality of studies was assessed using a modified checklist that included relevant sources of bias and assessment of quality of HSUV valuation and measurement. A descriptive analysis was conducted, including assessment on reporting of population characteristics and stratification of HSUV by potential health states or population subgroup. Results From 620 identified articles, ten reported HSUV. Seven studies reported HSUV of children with juvenile idiopathic arthritis, and three of adults with a history of juvenile idiopathic arthritis. Population disease activity status and drug treatment were reported in less than half of the studies. Six (out of ten) studies stratified HSUV results for at least one of the potential health state categories, but they represent very specific situations or interventions (e.g. patients receiving different types of physiotherapy or treated with etanercept over time). Conclusions We have identified critical gaps in the literature reporting HSUV in patients with juvenile idiopathic arthritis including a lack of HSUV measures for distinct health states, particularly in adults with a history of juvenile idiopathic arthritis. The current reported HSUV data in juvenile idiopathic arthritis are insufficient for a full cost-utility analysis with a short or lifetime horizon.Keywords
Funding Information
- Canadian Institutes of Health Research (381280)
- Genome Canada
- Reumafonds
- ZonMw
This publication has 43 references indexed in Scilit:
- Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping reviewPediatric Rheumatology, 2019
- Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force ReportValue in Health, 2019
- Trends in Population‐Based Incidence and Prevalence of Juvenile Idiopathic Arthritis in Manitoba, CanadaArthritis Care & Research, 2019
- Physical Functioning, Pain, and Health‐Related Quality of Life in Adults With Juvenile Idiopathic Arthritis: A Longitudinal 30‐Year Followup StudyArthritis Care & Research, 2017
- Juvenile idiopathic arthritis in adulthood: fulfilment of classification criteria for adult rheumatic diseases, long-term outcomes and predictors of inactive disease, functional status and damageRMD Open, 2016
- Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children RegisterAnnals Of The Rheumatic Diseases, 2014
- Conceptualizing a ModelMedical Decision Making, 2012
- Juvenile idiopathic arthritisThe Lancet, 2011
- Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritisArthritis Care & Research, 2008
- Valuing Health States for Use in Cost-Effectiveness AnalysisPharmacoEconomics, 2008